Alleged mishandling of discarded patient records call the giant retailer’s privacy safeguards into question
The data-focused CVS Caremark Corp. (Woonsocket, RI) has made an involuntary $2.25 million investment in protecting customer information and has fortified its procedures for handling retail trash. The investment takes the form of a fine from the Department of Health and Human Services, part of a two-pronged settlement in which the company agreed to implement appropriate procedures for handling personal information about customers and employees in response to an FTC complaint, and agreed to pay the fine and implement a corrective action plan for Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy rule compliance to settle with HHS.
"Through the settlement we are required to maintain our security policies and our employee training around them, and we are subject to inspections,” says Mike DeAngelis, CVS Caremark spokesman. Both matters stem from 2006 press reports alleging that patient information maintained by the pharmacy was being disposed of in unsecured industrial trash containers. According to FTC documents, “CVS Caremark made claims such as ‘CVS/pharmacy wants you to know that nothing is more central to our operations than maintaining the privacy of your health information,’” which FTC alleged was a deceptive claim.
HHS and FTC will also require CVS Caremark to actively monitor its compliance with the agreements. The company must hire a third party to assess CVS Caremark compliance and report to the federal agencies. The HHS corrective action plan will be in place for three years; the FTC requires monitoring for 20 years.
As a combination of one of the largest drugstore chains and one of the largest PBMs, CVS Caremark has big plans for becoming more central to healthcare IT specifically, and overall healthcare generally. In a recent BusinessWeek interview, CVS Caremark CEO Tom Ryan detailed the key role of customer data in the company’s strategy to grow while simultaneously helping to rein in healthcare costs through increased health monitoring and patient compliance, among other activities. Ryan said in the interview that the company’s customer data reveals when a customer has stopped taking medication. For PBM patients, that may prompt a telephone reminder from the store for the customer to get a refill.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.